Genmab: Janssen dispute cost DKK 146m in H1

Genmab's ongoing arbitration case with partner Janssen Pharmaceuticals has resulted in the latter withholding DKK 146m in royalty payments during the first half of 2021, the Danish biotech group informs.
Photo: Tuala Hjarnø / Genmab / PR
Photo: Tuala Hjarnø / Genmab / PR
BY ANDREAS LØNSTRUP, TRANSLATED BY DANIEL FRANK CHRISTENSEN

Even though Genmab's superseller, Darzalex, brought in USD 2.8bn in the first half of 2021 against USD 1.8bn from the same period last year – thereby playing a role in driving the recent guidance upgrade – the Danish biotech group is still able to note some less fortunate news for the period.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading